Related Experiment Video
Updated: Mar 6, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.5K
[New therapy approaches for Parkinson's disease]
K Brockmann1, D Berg2,3
1Zentrum für Neurologie, Abteilung Neurodegeneration, Hertie-Institut für klinische Hirnforschung, Deutsches Zentrum für Neurodegenerative Erkrankungen, Universität Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland. kathrin.brockmann@uni-tuebingen.de.
Der Nervenarzt
|March 15, 2017
Summary
Recent advances identify Parkinson's disease pathways like mitochondrial dysfunction, paving the way for new causative and disease-modifying treatments. These strategies aim to improve patient quality of life.
Area of Science:
- Neuroscience
- Pathophysiology
- Pharmacology
Background:
- Significant progress in identifying specific pathophysiological pathways in Parkinson's disease subgroups.
- Key pathways implicated include mitochondrial dysfunction, lysosomal dysfunction, and inflammatory patterns.
Purpose of the Study:
- To highlight novel causative and disease-modifying treatment strategies for Parkinson's disease.
- To discuss potential treatments applicable to patient subgroups and idiopathic Parkinson's disease.
- To emphasize the importance of improving quality of life for Parkinson's patients.
Main Methods:
- Review of recent scientific literature on Parkinson's disease pathophysiology.
- Analysis of identified pathways and their therapeutic implications.
- Focus on emerging treatment strategies targeting disease mechanisms.
Main Results:
- Identification of distinct pathophysiological pathways in Parkinson's disease subgroups.
- Establishment of these pathways as a basis for new therapeutic approaches.
- Potential for treatments to modify disease course and improve outcomes.
Conclusions:
- New causative and disease-modifying treatments for Parkinson's disease are emerging based on identified pathways.
- These strategies offer hope for both specific patient subgroups and the broader idiopathic Parkinson's disease population.
- Focusing on these pathways can lead to improved quality of life for individuals with Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:28Drug Therapy
346
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
346
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:21EPS and iPS Cells in Disease Research
3.5K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.5K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K